Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom

Patent Covers Novel DP2 (CRTH2) Receptor Antagonists for the Treatment of Respiratory Disorders

SAN DIEGO, May 26, 2010 - Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual
Property Office has granted patent number GB2461629, titled, "HETEROALKYL
ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS," which includes coverage of
Amira's AM461 DP2 receptor antagonist.

This is the second patent granted of a large estate filed by Amira
Pharmaceuticals that describe novel small molecule inhibitors of the DP2
(CRTH2) receptor. Amira has successfully completed Phase 1 studies on two DP2
receptor antagonists, AM211 and AM461, and anticipates these compounds will
be developed for the treatment of respiratory diseases such as asthma,
chronic obstructive pulmonary disease (COPD) and other allergic conditions.

"This UK patent for AM461 is another significant milestone for the Amira
DP2 program and clearly shows that Amira can effectively develop
patent-protected, novel drug candidates," said John Hutchinson, Ph.D., Vice
President of Chemistry.

Bob Baltera, Chief Executive Officer of Amira, added, "This patent
demonstrates Amira's continued focus on developing robust programs with
strong patent protection, rather than single drug candidates. We plan to use
the same strategy in our continued development of our research programs,
including our LPA program."

The newly granted claims cover novel phenoxyphenyl acetic acid compounds,
their formulation and uses in Prostaglandin D2 (PGD2)-dependent conditions.
The patent also describes the method of synthesis of this class of DP2
antagonists and their routes of administration for the treatment of DP2
receptor-mediated diseases and conditions.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is
a small molecule pharmaceutical company focused on the discovery and early
development of new drugs to treat inflammatory disease. Our discovery team is
building on unparalleled insights into bioactive lipid pathways and complex
signaling processes controlling many conditions including asthma, chronic
obstructive pulmonary disease, cardiovascular and fibrotic diseases. Amira
has a partnership with GlaxoSmithKline for the development of FLAP
(5-lipoxygenase activating protein) inhibitors in respiratory and
cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the
ingenuity and energy of a small company, creating an environment for
efficient development of novel compounds and effective pre-clinical and
clinical program decisions. Its scientific founders have successfully worked
together for more than a decade and were pivotal in the discovery of a number
of inflammatory drugs, including Singulair(R). The drug hunters at Amira are
now actively leveraging their history of success to create high-value
compounds for the future. For more information, visit
www.amirapharm.com.

Ian Stone of Russo Partners, +1-619-528-2220, ian.stone at russopartnersllc.com, for Amira Pharmaceuticals, Inc.